ROKIT America, which is anti-aging supplement provider spun out of South Korea's ROKIT Healthcare, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering.
The company develops and sells dietary supplements focused on cellular health and aging-related wellness, primarily centered on β-Nicotinamide Mononucleotide (NMN) formulations. Its flagship products combine NMN with additional ingredients such as pterostilbene and fisetin, and are marketed in the US and other global markets as consumer wellness supplements. In addition to its supplement business, the company is developing an AI-enabled organ regeneration platform through technology from its parent, ROKIT Healthcare, aimed at future regenerative medicine applications in the Americas. The company’s products are regulated as dietary supplements and do not require premarket approval by the FDA.
The Los Angeles, CA-based company was founded in 2012 and booked $7 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol RKAM. ROKIT America filed confidentially on October 2, 2025. Maxim Group LLC is the sole bookrunner on the deal.
